
<DOC>
<DOCNO>
WSJ900802-0170
</DOCNO>
<DOCID>
900802-0170.
</DOCID>
<HL>
   Rhone-Poulenc, Rorer Merger
</HL>
<DATE>
08/02/90
</DATE>
<SO>
WALL STREET JOURNAL (J), PAGE A2
</SO>
<CO>
   RPR RP.C
</CO>
<IN>
TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)
DRUG MANUFACTURERS (DRG)
</IN>
<LP>
   PARIS -- Rhone-Poulenc S.A. and Rorer Group Inc. of the
U.S. said they completed the merger of their human
pharmaceutical divisions.
   The creation of Rhone-Poulenc Rorer Inc. follows approval
by the Rorer shareholders' meeting Tuesday. Fort Washington,
Pa.-based Rorer will now assume $264 million of Rhone-Poulenc
debt to balance 20.9 million Rhone-Poulenc contingent value
rights, which will be distributed Aug. 9, 1990, to Rorer
shareholders.
</LP>
<TEXT>
   Rhone-Poulenc said it will hold 68% of the new company.
The remaining 32% of ordinary shares will continue to be
quoted on the New York Stock Exchange under the RPR symbol.
Meantime, the contingent value rights, will be traded on the
American Stock Exchange under the acronym RCV.
</TEXT>
</DOC>